Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas

Cancer

Volumn 78, Issue 2, 1996, Pages 287-293

  Tsuzuki, Toshihide ^a   Tsunoda, Shigeru ^b   Sakaki, Toshisuke ^a   Konishi, Noboru ^a   Hiasa, Yoshio ^a   Nakamura, Mitsutoshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Osaka Prefecture University   (Japan)

Author keywords

cell cycle; human astrocytomas; p15; p16(CDKN2); p53; RB

Indexed keywords

PROTEIN P15; PROTEIN P16; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA; CANCER INCIDENCE; CLINICAL ARTICLE; GENE LOCATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REGULATOR GENE; RETINOBLASTOMA; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ASTROCYTOMA; BLOTTING, WESTERN; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL CYCLE PROTEINS; CODON; CODON, TERMINATOR; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ENZYME INHIBITORS; EXONS; G1 PHASE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; GENES, P53; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; S PHASE; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS;

EID: 0030056824     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960715)78:2<287::AID-CNCR15>3.0.CO;2-S     Document Type: Article

References (38)

1. Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbender F, Xu H-J, et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994;36:714-21.
2. Nigro JM, Baker SA, Preisinger AC, Jessup JM, Hosteller R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989;342:705-8.
3. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 1992;52:674-9.
4. von Deimling A, Eibl RH, Ohgaki H, Louis DN, von Ammon K, Petersen I, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992;52:2987-90.
5. Lee W-H, Bookstein R, Hong F. Human retinoblastoma susceptibility gene: cloning, identification and sequence. Science 1987;235:1392-9.
6. Friend SH, Horowitz JM, Gerber MR, Wang X-F, Bogenmann E, Frederick PL, et al. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci USA 1987;84:9059-63.
7. McGee TL, Yandell DW, Dryja TP. Structure and partial genomic sequence of the human retinoblastoma susceptibility gene. Gene 1989;80:119-28.
8. Harbour JW, Lai SL, Wang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988;24:353-7.
9. Horowitz JM, Yandell DW, Park S-H, Canning S, Whyte P, Buchkovich K, et al. Point mutational inactivation of the retinoblastoma antioncogene. Science 1989;243:937-40.
10. Lee EY-HP, To H, Shew J-Y, Bookstein R, Scully P, Lee W-H. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 1988;241:218-21.
11. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibitor of cyclin D/ CDK4. Nature 1993;366:704-7.
12. INK4, the product of the putative tumor suppressor gene MTS. Oncogene 1994;9:3475-82.
13. INK4. Science 1995;297:249-52.
14. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
15. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
16. Hogg A, Onadim Z, Baird PN, Cowell JK. Detection of heterozygous mutations in the RB1 gene in retinoblastoma patients using single-strand conformation polymorphism analysis and polymerase chain reaction sequencing. Oncogene 1992;7:1445-51.
17. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991;51:4090-6.
18. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
19. Zhang S-Y, Klein-S AJ, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994;54:5050-3.
20. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, et al. In vivo occurrence of p16 (MTS1) and 15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 1995;55:514-7.
21. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain terminating inhibitor. Proc Natl Acad Sci USA 1977; 74:5463-7.
22. James CD, Carlbom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988;48:5546-51.
23. Fults D, Pedone CA, Thomas GA, White R. Allelotype of human malignant astrocytoma. Cancer Res 1990;50:5784-9.
24. Frankel RH, Bayona W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992; 52:1427-33.
25. Mori N, Yokota J, Akiyama T, Sameshima Y, Okamoto A, Mizoguchi H, et al. Variable mutations of the RB gene in small cell lung carcinoma. Oncogene 1990;5:1713-7.
26. Ishikawa J, Xu H-J, Hu S-X, Yandell DW, Maeda S, Kamidono S, et al. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 1991;51:5736-43.
27. Dianzani I, Camaschella C, Ponzone A, Cotton RGH. Dilemmas and progress in mutation detection. Trends Genet 1993;9:403-5.
28. Sakai T, Ohtani N, McGee TL, Robbins PD, Dryja TP. Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature 1991;353:83-6.
29. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 1993;8:1063-7.
30. INK4 protein is restricted to the subset of lung cancer lines that retains wild type RB. Oncogene 1994; 9:3375-8.
31. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRB. Cancer Res 1994;54:6078-82.
32. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRB alterations in human urothelial cells. Cancer Res 1995;55:493-7.
33. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54:6321-4.
34. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994;54:6353-8.
35. Beltinger CP, White PS, Sukman EP, Maris JM, Brodeur GM. No CDKN2 mutations in neuroblastomas. Cancer Res 1995;55:2053-5.
36. Nakamura M, Konishi N, Hiasa Y, Tsunoda S, Fukushima Y, Tsuzuki T, et al. Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors. Int J Oncol 1996;8:889-93.
37. INK4 expression is frequent in high grade gliomas. Cancer Res 1995;55:1941-5.
38. INK4 or retinoblastoma protein (pRB), or amplification-associated overexpression of cdk-4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995;55:4833-6.